{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T04:18:16Z","timestamp":1769919496037,"version":"3.49.0"},"reference-count":25,"publisher":"American Diabetes Association","issue":"8","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,8,1]]},"abstract":"<jats:p>OBJECTIVE\u20141,5-anhydroglucitol (1,5-AG) is a short-term marker of metabolic control in diabetes. Its renal loss is stimulated in hyperglycemic conditions by glycosuria, which results in a lowered plasma concentration. As a low renal threshold for glucose has been described in hepatocyte nuclear factor-1\u03b1 (HNF-1\u03b1) maturity-onset diabetes of the young (MODY), the 1,5-AG level may be altered in these patients. The purpose of this study was to assess the 1,5-AG levels in patients with HNF-1\u03b1 MODY and in type 2 diabetic subjects with a similar degree of metabolic control. In addition, we aimed to evaluate this particle as a biomarker for HNF-1\u03b1 MODY.<\/jats:p>\n               <jats:p>RESEARCH DESIGN AND METHODS\u2014We included 33 diabetic patients from the Polish Nationwide Registry of MODY. In addition, we examined 43 type 2 diabetic patients and 47 nondiabetic control subjects. The 1,5-AG concentration was measured with an enzymatic assay (GlycoMark). Receiver operating characteristic (ROC) curve analysis was used to evaluate 1,5-AG as a screening marker for HNF-1\u03b1 MODY.<\/jats:p>\n               <jats:p>RESULTS\u2014The mean 1,5-AG plasma concentration in diabetic HNF-1\u03b1 mutation carriers was 5.9 \u03bcg\/ml, and it was lower than that in type 2 diabetic patients (11.0 \u03bcg\/ml, P = 0.003) and in nondiabetic control subjects (23.9 \u03bcg\/ml, P &amp;lt; 0.00005). The ROC curve analysis revealed 85.7% sensitivity and 80.0% specificity of 1,5-AG in screening for HNF-1\u03b1 MODY at the criterion of &amp;lt;6.5 \u03bcg\/ml in patients with an A1C level between 6.5 and 9.0%.<\/jats:p>\n               <jats:p>CONCLUSIONS\u20141,5-AG may be a useful biomarker for differential diagnosis of patients with HNF-1\u03b1 MODY with a specific range of A1C, although this requires further investigation. However, the clinical use of this particle in diabetic HNF-1\u03b1 mutation carriers for metabolic control has substantial limitations.<\/jats:p>","DOI":"10.2337\/dc07-2334","type":"journal-article","created":{"date-parts":[[2008,6,7]],"date-time":"2008-06-07T00:49:14Z","timestamp":1212799754000},"page":"1496-1501","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":26,"title":["Clinical Application of 1,5-Anhydroglucitol Measurements in Patients with Hepatocyte Nuclear Factor-1\u03b1 Maturity-Onset Diabetes of the Young"],"prefix":"10.2337","volume":"31","author":[{"given":"Jan","family":"Skupien","sequence":"first","affiliation":[{"name":"Department of Metabolic Diseases, Jagiellonian University, Medical College, Krakow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylwia","family":"Gorczynska-Kosiorz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Diabetology and Nephrology, Silesian School of Medicine, Zabrze, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Klupa","sequence":"additional","affiliation":[{"name":"Department of Metabolic Diseases, Jagiellonian University, Medical College, Krakow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Wanic","sequence":"additional","affiliation":[{"name":"Department of Metabolic Diseases, Jagiellonian University, Medical College, Krakow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric A.","family":"Button","sequence":"additional","affiliation":[{"name":"BioMarker Group, Kannapolis, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacek","family":"Sieradzki","sequence":"additional","affiliation":[{"name":"Department of Metabolic Diseases, Jagiellonian University, Medical College, Krakow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej T.","family":"Malecki","sequence":"additional","affiliation":[{"name":"Department of Metabolic Diseases, Jagiellonian University, Medical College, Krakow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","reference":[{"key":"2022031219215810600_R1","doi-asserted-by":"crossref","unstructured":"Yamanouchi T, Tachibana Y, Akanuma H: Origin and disposal of 1,5-anhydroglucitol, a major polyol in the human body. Am J Physiol\u2008263: E268\u2013E273, 1992","DOI":"10.1152\/ajpendo.1992.263.2.E268"},{"key":"2022031219215810600_R2","doi-asserted-by":"crossref","unstructured":"Yamanouchi T, Shinohara T, Ogata N, Tachibana Y, Akaoka I, Miyashita H: Common reabsorption system of 1,5-anhydro-d-glucitol, fructose, and mannose in rat renal tubule. Biochim Biophys Acta\u20081291:89\u201395, 1996","DOI":"10.1016\/0304-4165(96)00050-5"},{"key":"2022031219215810600_R3","unstructured":"Saito H, Ohtomo T, Inui K: Na+-dependent uptake of 1,5-anhydro-d-glucitol via the transport systems for d-glucose and d-mannose in the kidney epithelial cell line, LLC-PK1. Nippon Jinzo Gakkai Shi\u200838:435\u2013440, 1996"},{"key":"2022031219215810600_R4","doi-asserted-by":"crossref","unstructured":"Stickle D, Turk J: A kinetic mass balance model for 1,5-anhydroglucitol: applications to monitoring of glycemic control. Am J Physiol\u2008273:E821\u2013E830, 1997","DOI":"10.1152\/ajpendo.1997.273.4.E821"},{"key":"2022031219215810600_R5","doi-asserted-by":"crossref","unstructured":"Yamanouchi T, Ogata N, Tagaya T, Kawasaki T, Sekino N, Funato H, Akaoka L, Miyashita H: Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control. Lancet\u2008347:1514\u20131518, 1996","DOI":"10.1016\/S0140-6736(96)90672-8"},{"key":"2022031219215810600_R6","doi-asserted-by":"crossref","unstructured":"Dungan KM, Buse JB, Largay J, Kelly MM, Button EA, Kato S, Wittlin S: 1,5-Anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care\u200829:1214\u20131219, 2006","DOI":"10.2337\/dc06-1910"},{"key":"2022031219215810600_R7","doi-asserted-by":"crossref","unstructured":"Kilpatrick ES, Keevilt BG, Richmond KL, Newland P, Addison GM: Plasma 1,5-anhydroglucitol concentrations are influenced by variations in the renal threshold for glucose. Diabet Med\u200816:496\u2013499, 1999","DOI":"10.1046\/j.1464-5491.1999.00093.x"},{"key":"2022031219215810600_R8","doi-asserted-by":"crossref","unstructured":"Emoto M, Tabata T, Inoue T, Nishizawa Y, Morii H: Plasma 1,5-anhydroglucitol concentration in patients with end-stage renal disease with and without diabetes mellitus. Nephron\u200861:181\u2013186, 1992","DOI":"10.1159\/000186868"},{"key":"2022031219215810600_R9","doi-asserted-by":"crossref","unstructured":"Menzel R, Kaisaki PJ, Rjasanowski I, Heinke P, Kerner W, Menzel S: A low renal threshold for glucose in diabetic patients with a mutation in the hepatocyte nuclear factor-1\u03b1 (HNF-1\u03b1) gene. Diabet Med\u200815:816\u2013820, 1998","DOI":"10.1002\/(SICI)1096-9136(199810)15:10<816::AID-DIA714>3.0.CO;2-P"},{"key":"2022031219215810600_R10","doi-asserted-by":"crossref","unstructured":"Stride A, Ellard S, Clark P, Shakespeare L, Salzmann M, Shepherd M, Hattersley AT: \u03b2-Cell dysfunction, insulin sensitivity, and glycosuria precede diabetes in hepatocyte nuclear factor-1\u03b1 mutation carriers. Diabetes Care\u200828:1751\u20131756, 2005","DOI":"10.2337\/diacare.28.7.1751"},{"key":"2022031219215810600_R11","doi-asserted-by":"crossref","unstructured":"Pontoglio M, Prie D, Cheret C, Doyen A, Leroy C, Froguel P, Velho G, Yaniv M, Friedlander G: HNF1\u03b1 controls renal glucose reabsorption in mouse and man. EMBO Rep\u20081:359\u2013365, 2000","DOI":"10.1093\/embo-reports\/kvd071"},{"key":"2022031219215810600_R12","doi-asserted-by":"crossref","unstructured":"Malecki MT, Skupien J, Gorczynska-Kosiorz S, Klupa T, Nazim J, Moczulski DK, Sieradzki J: Renal malformations may be linked to mutations in the hepatocyte nuclear factor-1\u03b1 (MODY3) gene. Diabetes Care\u200828:2774\u20132776, 2005","DOI":"10.2337\/diacare.28.11.2774"},{"key":"2022031219215810600_R13","doi-asserted-by":"crossref","unstructured":"Bochenski J, Placha G, Wanic K, Malecki M, Sieradzki J, Warram JH, Krolewski AS: New polymorphism of ENPP1 (PC-1) is associated with increased risk of type 2 diabetes among obese individuals. Diabetes\u200855:2626\u20132630, 2006","DOI":"10.2337\/db06-0191"},{"key":"2022031219215810600_R14","doi-asserted-by":"crossref","unstructured":"Nowatzke W, Sarnob MJ, Birchc NC, Sticklec DF, Edend T, Cole TG: Evaluation of an assay for serum 1,5-anhydroglucitol (GlycoMark) and determination of reference intervals on the Hitachi 917 analyzer. Clin Chim Acta\u2008350:201\u2013209, 2004","DOI":"10.1016\/j.cccn.2004.08.013"},{"key":"2022031219215810600_R15","doi-asserted-by":"crossref","unstructured":"Dworacka M, Wender-Ozegowska E, Winiarska H, Borowska M, Zawiejska A, Pietryga M, Brazert J, Szczawinska K, Bobkiewicz-Koz\u0142owska T: Plasma anhydro-d-glucitol (1,5-AG) as an indicator of hyperglycaemic excursions in pregnant women with diabetes. Diabet Med\u200823:171\u2013175, 2006","DOI":"10.1111\/j.1464-5491.2005.01752.x"},{"key":"2022031219215810600_R16","doi-asserted-by":"crossref","unstructured":"Yamanouchi T, Akanuma Y, Toyota T, Kuzuya T, Kawai T, Kawazu S, Yoshioka S, Kanazawa Y, Ohta M, Baba S: Comparison of 1,5-anhydroglucitol, A1C, and fructosamine for detection of diabetes mellitus. Diabetes\u200840:52\u201357, 1991","DOI":"10.2337\/diabetes.40.1.52"},{"key":"2022031219215810600_R17","doi-asserted-by":"crossref","unstructured":"Robertson DA, Alberti KG, Dowse GK, Zimmet P, Tuomilehto J, Gareeboo H: Is serum anhydroglucitol an alternative to the oral glucose tolerance test for diabetes screening? The Mauritius Noncommunicable Diseases Study Group. Diabet Med\u200810:56\u201360, 1993","DOI":"10.1111\/j.1464-5491.1993.tb01997.x"},{"key":"2022031219215810600_R18","doi-asserted-by":"crossref","unstructured":"Phillipou G, James SK, Frith RG, Farrant RK, Phillips PJ: Enzymatic quantification of 1,5-anhydro-d-glucitol: evaluation and clinical application. Clin Chem\u200840:1322\u20131326, 1994","DOI":"10.1093\/clinchem\/40.7.1322"},{"key":"2022031219215810600_R19","doi-asserted-by":"crossref","unstructured":"Monnier L, Lapinski H, Colette C: Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of A1C. Diabetes Care\u200826:881\u2013885, 2003","DOI":"10.2337\/diacare.26.3.881"},{"key":"2022031219215810600_R20","doi-asserted-by":"crossref","unstructured":"Stride A, Vaxillaire M, Tuomi T, Barbetti F, Nj\u00f8lstad PR, Hansen T, Costa A, Conget I, Pedersen O, S\u00f8vik O, Lorini R, Groop L, Froguel P, Hattersley AT: The genetic abnormality in the \u03b2 cell determines the response to an oral glucose load. Diabetologia\u200845:427\u2013435, 2002","DOI":"10.1007\/s00125-001-0770-9"},{"key":"2022031219215810600_R21","doi-asserted-by":"crossref","unstructured":"Stride A, Hattersley AT: Different genes, different diabetes: lessons from maturity-onset diabetes of the young. Ann Med\u200834:207\u2013216, 2002","DOI":"10.1080\/ann.34.3.207.217"},{"key":"2022031219215810600_R22","doi-asserted-by":"crossref","unstructured":"Pearson ER, Pruhova S, Tack CJ, Johansen A, Castleden HA, Lumb PJ, Wierzbicki AS, Clark PM, Lebl J, Pedersen O, Ellard S, Hansen T, Hattersley AT: Molecular genetics and phenotypic characteristics of MODY caused by hepatocyte nuclear factor 4\u03b1 mutations in a large European collection. Diabetologia\u200848:878\u2013885, 2005","DOI":"10.1007\/s00125-005-1738-y"},{"key":"2022031219215810600_R23","doi-asserted-by":"crossref","unstructured":"Kaisaki PJ, Menzel S, Lindner T, Oda N, Rjasanowski I, Sahm J, Meincke G, Schulze J, Schmechel H, Petzold C, Ledermann HM, Sachse G, Boriraj VV, Menzel R, Kerner W, Turner RC, Yamagata K, Bell GI: Mutations in the hepatocyte nuclear factor-1\u03b1 gene in MODY and early-onset NIDDM: evidence for a mutational hotspot in exon 4. Diabetes\u200846:528\u2013535, 1997","DOI":"10.2337\/diab.46.3.528"},{"key":"2022031219215810600_R24","doi-asserted-by":"crossref","unstructured":"Pearson ER, Velho G, Clark P, Stride A, Shepherd M, Frayling TM, Bulman MP, Ellard S, Froguel P, Hattersley AT: \u03b2-Cell genes and diabetes: quantitative and qualitative differences in the pathophysiology of hepatic nuclear factor-1\u03b1 and glucokinase mutations. Diabetes\u200850(Suppl. 1):S101\u2013S107, 2001","DOI":"10.2337\/diabetes.50.2007.S101"},{"key":"2022031219215810600_R25","doi-asserted-by":"crossref","unstructured":"Iwasaki N, Oda N, Ogata M, Hara M, Hinokio Y, Oda Y, Yamagata K, Kanematsu S, Ohgawara H, Omori Y, Bell GI: Mutations in the hepatocyte nuclear factor-1\u03b1\/MODY3 gene in Japanese subjects with early- and late-onset NIDDM. Diabetes\u200846:1504\u20131508, 1997","DOI":"10.2337\/diab.46.9.1504"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/31\/8\/1496\/599597\/zdc00808001496.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/31\/8\/1496\/599597\/zdc00808001496.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T20:50:26Z","timestamp":1647118226000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/31\/8\/1496\/28593\/Clinical-Application-of-1-5-Anhydroglucitol"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,1]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,8,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc07-2334","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,1]]}}}